Mapping the first steps to a coronavirus vaccine
By Poppy Wilson
The past couple of months have seen a certain viral disease increasingly dominate the news, and unsparingly steal our headlines. Covid-19, a simple abbreviation of “coronavirus disease 2019”, has surpassed 80,000 cases in the last week. The first actively spreading population has appeared in Europe, in Northern Italy. Covid-19 is likely to remain in the spotlight for the near future. So what progress has been made towards stopping this disease?
Pangolins are a chief suspect of the true source of the outbreak
Covid-19 is caused by a novel strain of coronavirus capable of infecting humans: severe acute respiratory syndrome coronavi-rus 2 (SARS-CoV-2). The disease provokes a fever followed by a dry cough, and is believed to only be life-threatening to those with a weakened immune system. Despite this, however, the rapid spread of the disease from its sup- posed place of origin in a seafood market (however a recent paper claims this was not the case) in Wuhan, China has left researchers scrambling to develop a vaccine.
On January 10th, the genome encoding the virus was released after intense sequencing. The data revealed SARS-CoV-2 originated in bats. However, bats were not for sale at the Wuhan Seafood Market, necessitating the existence of an intermediate animal host that enabled the virus to jump from bats to humans.
Identifying the true source of the virus is ongoing, though pangolins are a chief suspect. Nevertheless, the genome sequence has facilitated some resolute discoveries. Last week, utilising the genomic data, a team of scientists published a 3D map of the virus’ “spike” protein – the very protein previously shown to enable coronavirus cellular invasion.
The spike protein is located on the viral surface where it binds to human cell receptors. These receptors act as gateway proteins since once bound, a shape change within the spike protein is initiated, enabling viral fusion with the human cell membrane. At this point, the cell is infected.
A vaccine could be available within two years
Consequently, mapping of this protein is a major advancement in development of a Covid-19 vaccine, providing us with a target to work towards. This target structure within the vaccine, termed antigen, is what our bodies develop antibodies against, seeding immunity.
Mutations have already been introduced into the protein to increase structural stability for future vaccine-based work. Indeed, the vaccine company Novavax has already developed several vaccine candidates utilising the spike protein. Currently working in animals, they aim to commence human trials by the end of spring. Novavax joins several other organisations and pharmaceutical companies racing to cultivate successful Covid-19 therapeutics. These include bio-tech firm Moderna, creators of an experimental messenger RNA (mRNA) coronavirus vaccine. Interestingly, mRNA vaccines are cheaper and faster to produce, though their efficacy remains, thus far, unverified.
Work towards a vaccine is gathering mass with extreme speed, with some scientists and the World Health Organisation (WHO) claiming a vaccine could be available in 18 to 24 months; that is, much more quickly than normal vaccine development, which can take 10 years. Indeed, it was four months into the Sars coronavirus outbreak in 2003 before the genome sequence for this contagion was even obtained. This highlights not only technological advancements but also the power of harnessing global efforts, the latter being something that also sped up development of the Ebola vaccine.
The outbreak of this novel coronavirus poses a pandemic threat of international concern. This serious threat, however, has ignited innovation and collaboration, leading to promising vaccine development. This process is complicated, and there are still many hurdles to overcome, but the achievements so far provide hope in the face of a seemingly tireless foe.
Image: NiAID via Flickr
